Ana Belén Ortiz-Haro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Belén Ortiz-Haro has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Irazú Contreras-Yáñez
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2 shared publications - Virginia Pascual-Ramos
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México
2 shared publications Abril Verónica Mendoza-Vigueras
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán, Tlalpan, Mexico City, Mexico
1 shared publication- Diana Isabel Perez Roman
Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas Mexico City Mexico
1 shared publication - Emmanuel Ruiz-Medrano
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga n° 15, Colonia Belisario Domínguez Sección XVI, 14080, Ciudad de México, Mexico
1 shared publication Frida Carvajal-Medina
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador-Zubirán, Tlalpan, Mexico City, Mexico
1 shared publication
Latest Publications
- 24 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6091-6102
Prevalence and transient impact of childhood abuse and neglect on health-related quality of life in Mexican patients with early rheumatoid arthritis
- 24 August 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (10) , 6091-6102
Prevalence and transient impact of childhood abuse and neglect on health-related quality of life in Mexican patients with early rheumatoid arthritis
- 20 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 599-606
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation
To describe disease activity and disability during the first year of follow-up, from rheumatoid arthritis (RA) patients who discontinue tofacitinib after they end participation in a clinical trial. From 2008 to 2016, 36 patients were enrolled in the “Long term follow-up study with tofacitinib (and methotrexate) for RA treatment”. At the end of the study, tofacitinib was discontinued and patients were proposed to enter an observational study; 35 agree and had scheduled evaluations at baseline, at 15 and 30 days of follow-up, at month 2 and 3, and thereafter every 3 months. Disease activity was evaluated as per DAS28-ESR and disability as per HAQ. During follow-up, treatment was treat-to-target oriented, only conventional DMARDs were indicated. Descriptive statistics and nonparametric test were used. The study was approved by IRB. Patients were primarily females (N = 34), had median (Q25–75) age of 52 years (45–58), and had received tofacitinib for a median of 7.9 years (6.3–8.3). The proportion of patients with remission and low disease activity decreased from day 30 of follow-up and recovered after 270 days, meanwhile patients with high disease activity increased from 0% at baseline to 6.3% at 1 year. At study entry, 20 patients had remission/low disease activity; during follow-up, 85% deteriorated after (median) 30 days; among them, 23.5% recovered their baseline status after a median of 172.5 days. The HAQ showed a similar behavior, but 66.7% recovered. A substantial proportion of RA patients deteriorated outcomes early after tofacitinib cessation; some patients recovered baseline status with traditional DMARDS.
- 20 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 599-606
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation
To describe disease activity and disability during the first year of follow-up, from rheumatoid arthritis (RA) patients who discontinue tofacitinib after they end participation in a clinical trial. From 2008 to 2016, 36 patients were enrolled in the “Long term follow-up study with tofacitinib (and methotrexate) for RA treatment”. At the end of the study, tofacitinib was discontinued and patients were proposed to enter an observational study; 35 agree and had scheduled evaluations at baseline, at 15 and 30 days of follow-up, at month 2 and 3, and thereafter every 3 months. Disease activity was evaluated as per DAS28-ESR and disability as per HAQ. During follow-up, treatment was treat-to-target oriented, only conventional DMARDs were indicated. Descriptive statistics and nonparametric test were used. The study was approved by IRB. Patients were primarily females (N = 34), had median (Q25–75) age of 52 years (45–58), and had received tofacitinib for a median of 7.9 years (6.3–8.3). The proportion of patients with remission and low disease activity decreased from day 30 of follow-up and recovered after 270 days, meanwhile patients with high disease activity increased from 0% at baseline to 6.3% at 1 year. At study entry, 20 patients had remission/low disease activity; during follow-up, 85% deteriorated after (median) 30 days; among them, 23.5% recovered their baseline status after a median of 172.5 days. The HAQ showed a similar behavior, but 66.7% recovered. A substantial proportion of RA patients deteriorated outcomes early after tofacitinib cessation; some patients recovered baseline status with traditional DMARDS.